Regenerative Medicine for Longevity in Saudi Arabia: What's Actually Happening

Saudi Arabia has become one of the most heavily funded players in global longevity science, driven almost entirely by one institution: the Riyadh-based Hevolution Foundation, a nonprofit established by royal order in 2018 and chaired by Crown Prince Mohammed bin Salman. Hevolution now describes itself as among the largest philanthropic funders of geroscience in the world, backing everything from basic aging biology to a $40 million aging-reversal competition. At the same time, Saudi Arabia faces a familiar problem: public enthusiasm for stem cell and anti-aging treatments is running well ahead of public understanding of what's actually approved, creating an opening for unregulated clinics. This article separates the two: what's real and well-documented on the funding and research side, and what's genuinely unresolved on the clinical-access side.

The Money Behind the Push

Hevolution operates with an annual budget reported at over $1 billion, and by early 2025 it had deployed more than $400 million in research grants and early-stage biotech investments over roughly 20 months, according to Al Arabiya English's coverage of the foundation's work. Its single largest commitment is the $230 million Geroscience Research Opportunities Program, funding pre-clinical aging biology and translational geroscience research globally. Hevolution has also put $40 million behind the XPRIZE Healthspan competition, which challenges research teams to demonstrably reverse measurable aging markers in older adults — one of the more concrete, outcome-based bets in the field.

Beyond the headline programs, Hevolution has funded named academic efforts at Northwestern University ($32.4 million, proteostasis research), the Buck Institute ($21 million), and Albert Einstein College of Medicine ($20 million, senescence research), plus smaller commitments to Harvard, MIT, and a $5 million Latin America initiative. It has also made commercial investments in companies including Aeovian Pharmaceuticals, Rubedo Life Sciences, and Vandria SA.

Building Domestic Research Capacity

Inside the Kingdom, Hevolution has funded a multi-year research grant program (reported at roughly $5.2 million) that created the country's first organized cohort of aging researchers, spanning 11 grantees at research institutions including King Abdullah University of Science and Technology (KAUST). A separate program is aimed specifically at developing early-career Saudi scientists in aging research, with additional postdoctoral fellowship funding reported for researchers in Saudi Arabia and the wider Gulf Cooperation Council. Hevolution's leadership has also said the foundation fed "vital inputs" into Saudi Arabia's National Biotechnology Strategy, suggesting its influence extends into national science policy, not just grant-making.

The scale of ambition was on display at the Global Healthspan Summit itself — Hevolution's flagship annual gathering in Riyadh, which drew more than 3,000 attendees in 2025 and has become a recurring fixture for the global aging-research community, with the foundation pledging hundreds of millions of dollars in new commitments at the event.

The Regulatory and Clinical Reality

This is where the picture gets more cautious. The Saudi Food and Drug Authority (SFDA) is the body responsible for regulating biological products in the Kingdom, including cell and gene therapies, and requires a marketing authorization roughly comparable to a U.S. Biologics License Application before a cellular product can be sold or marketed. Separately, stem cell sourcing in Saudi Arabia is governed by a 2003 religious ruling (fatwa) that permits collection from consenting adults, umbilical cord and placental tissue, and donated leftover IVF embryos, while prohibiting sourcing from willfully aborted fetuses or therapeutic cloning. Cord blood banking has a formal home in the country too: the Saudi Stem Cell Donor Registry was established by national health authorities in 2011.

What the SFDA's framework does not appear to have fully solved is the gap between formally approved cellular medicine and the broader marketplace of "regenerative" and anti-aging treatments offered commercially. A peer-reviewed cross-sectional study of 2,030 Saudi residents, published in Frontiers in Medicine, found that 72.1% of respondents did not know that unapproved stem cell treatments could cause serious complications, including cancer, and that roughly 1 in 5 believed stem cells were already an approved treatment for hair and facial care. Despite this, 63.6% said they would accept stem cell treatment for themselves or recommend it to others, and 85.4% said they were open to traveling abroad for such treatment. Notably, 60.6% of the physicians surveyed and 56.4% of medical students said they would recommend stem cell treatment to patients — a striking figure given how much of the underlying evidence base for many marketed "stem cell" and exosome products remains unapproved or investigational. The study's authors explicitly called for stronger government regulation of clinics and cited the International Society for Stem Cell Research's (ISSCR) guidelines, which call for enforcement action against unapproved treatments.

Who's Actually Driving This, and Who Isn't

It's worth being precise about what Saudi Arabia's longevity push currently is and isn't. It is a serious, well-capitalized basic-science and translational-research funding effort, anchored by a single sovereign-backed foundation with global reach — Hevolution funds labs at Harvard, Northwestern, and the Buck Institute as readily as it funds Saudi institutions. It is not, based on available evidence, a mature domestic clinical infrastructure with its own pipeline of SFDA-approved longevity therapeutics yet reaching patients at scale. The gap between "world's best-funded aging research philanthropy" and "regulated longevity clinic network" is real, and is one Saudi public health researchers themselves are flagging.

Bottom Line

Saudi Arabia's investment in longevity science is genuine, large, and increasingly influential globally — Hevolution's $400+ million deployed in under two years and its $230 million flagship research program put it in rare company among aging-research funders anywhere in the world. But that funding sits upstream of the clinic floor. The SFDA has a defined regulatory pathway for biological products, and a 2003 fatwa sets ethical sourcing boundaries for stem cells, yet published survey data shows most Saudi residents can't distinguish approved from unapproved stem cell treatments, and even many physicians say they would recommend therapies whose evidence base may not support that recommendation. Readers should treat the research-funding story and the clinical-treatment story as two different things moving at two different speeds — a well-funded national longevity strategy does not mean any given marketed "stem cell" or anti-aging clinic treatment has been validated or approved.